Mangoceuticals (MGRX) Stock Price, News & Analysis

Company Overview

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

Key Stats

• Today's Range: $1.62 to $1.71
• 50-Day Range: $1.43 to $2.42
• 52-Week Range: $1.32 to $7.66
• Volume: 53,827 shs
• Average Volume: 143,189 shs
• Market Capitalization: $8.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MGRX Stock Analysis - Frequently Asked Questions

How have MGRX shares performed this year?

Mangoceuticals' stock was trading at $2.42 at the start of the year. Since then, MGRX stock has decreased by 29.3% and is now trading at $1.71.

How were Mangoceuticals' earnings last quarter?

Mangoceuticals, Inc. (NASDAQ:MGRX) issued its earnings results on Thursday, May, 15th. The company reported ($1.29) EPS for the quarter. The business earned $0.11 million during the quarter. Mangoceuticals had a negative net margin of 2,191.76% and a negative trailing twelve-month return on equity of 72.81%.

When did Mangoceuticals' stock split?

Shares of Mangoceuticals reverse split before market open on Wednesday, October 16th 2024.The 1-15 reverse split was announced on Wednesday, October 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Mangoceuticals IPO?

Mangoceuticals (MGRX) raised $5 million in an initial public offering on Tuesday, March 21st 2023. The company issued 1,300,000 shares at $4.00 per share. Boustead Securities acted as the underwriter for the IPO.

How do I buy shares of Mangoceuticals?

Shares of MGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mangoceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mangoceuticals investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), MSP Recovery (LIFW), Advanced Micro Devices (AMD) and Charge Enterprises (CRGE).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:MGRX
• CIK: 1938046
• Web: www.mangorx.com
• Phone: 833-626-4679
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.71 million
• Net Margins: -2,191.76%
• Pretax Margin: -2,191.76%
• Return on Equity: -72.81%
• Return on Assets: -66.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.12
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: $511.08 thousand
• Price / Sales: 17.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.30 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 5,169,000
• Free Float: 4,342,000
• Market Cap: $8.84 million
• Optionable: Not Optionable
• Beta: 2.40